Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03617666 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study(AVENuE) | unknown | Phase 2 | 49 | University College, LondonOTHER | 2 | Dec 12, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 |
| clinicaltrials |
| NCT06029036 | A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer | unknown | Phase 2 | 53 | Peking University First HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05432934 | Transversus Abdominis Plane Blocks With and Without Dexamethasone(TAP-DEX) | unknown | Phase 1 / Phase 2 | 60 | University of SaskatchewanOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05578287 | RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer(DETECT) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06153368 | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06161272 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | unknown | Phase 2 | 80 | Guangxi Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01811394 | Ion Irradiation of Sacrococcygeal Chordoma(ISAC) | unknown | Phase 2 | 100 | Heidelberg UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | unknown | Phase 2 | 50 | Chunyan Sun, MDOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05820906 | Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156891 | PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05523609 | Vitamin D and Calcium Supplementation in Breast Cancer | unknown | Phase 2 / Phase 3 | 40 | Tanta UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | unknown | Phase 2 | 90 | Zhiyu WangOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05876806 | Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | unknown | Phase 2 | 30 | Se Jun ParkOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06151249 | Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy | unknown | Phase 2 | 32 | Chung Shan Medical UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | unknown | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05583175 | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT06146985 | Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | unknown | Phase 2 | 67 | Ruijin HospitalOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05329025 | A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03906669 | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.(WinPro) | unknown | Phase 2 | 200 | St Vincent's HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05580445 | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 114 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05709171 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | unknown | Phase 2 | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06107114 | Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma(CZCNRHNSCC) | unknown | Phase 2 | 52 | Xuekui LiuOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06143735 | A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors | unknown | Phase 2 | 99 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 50 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05918198 | Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Peking University People's HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06142318 | Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 66 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | unknown | Phase 2 | 30 | Xuanwu Hospital, BeijingOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05512520 | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）(EC-CRT-003) | unknown | Phase 2 | 126 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05812534 | Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases(CBC) | unknown | Phase 2 | 36 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06103617 | Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer | unknown | Phase 2 | 10 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06134765 | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | unknown | Phase 2 | 89 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab(OpACIN-neo) | unknown | Phase 2 | 186 | The Netherlands Cancer InstituteOTHER | 4 | Nov 15, 2023 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 12, 2023source: clinicaltrials